Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03769662




Registration number
NCT03769662
Ethics application status
Date submitted
6/12/2018
Date registered
7/12/2018
Date last updated
18/01/2020

Titles & IDs
Public title
Follow on Extension of XT-150-1-0201
Scientific title
XT-150-1-0201 Extension: Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain
Secondary ID [1] 0 0
XT-150-1-0203
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Osteoarthritis, Knee 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - XT-150

Experimental: High dose from study XT-150-1-0201 - Open label administration of the highest dose in the earlier study, in which all doses were well tolerated


Other interventions: XT-150
IL-10 transgene DNA plasmid injected into the knee synovial capsule
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Treatment-Emergent Adverse Events
Timepoint [1] 0 0
6 months
Secondary outcome [1] 0 0
Verbal Numeric Rating Score
Timepoint [1] 0 0
6 months
Secondary outcome [2] 0 0
KOOS
Timepoint [2] 0 0
6 months
Secondary outcome [3] 0 0
Brief Pain Inventory
Timepoint [3] 0 0
6 months
Secondary outcome [4] 0 0
Clinical Global Improvement
Timepoint [4] 0 0
6 months

Eligibility
Key inclusion criteria
1. Qualified and participated in clinical study XT-150-1-0201.

1. Participant was assigned to placebo, or

2. Participant elects to have XT-150 administered to the XT-150-untreated knee that
qualified under XT-150-1-0201 criteria, or

3. Participant had inadequate pain relief and elects to receive a second injection
to the same knee treated on clinical study XT-150-1-0201

2. Sufficiently severe OA of knee to require/have recommended knee replacement surgery or
be unsuitable for knee replacement surgery based on co-morbidities or orthopedic
considerations; be free of local or intra-articular infection.

3. Symptomatic disease because of osteoarthritis, defined as a Verbal Numerical Rating
Scale (VNRS) scores of a worst pain of at least 7 at any time during the preceding
week (based on scale of 0 to 10, with 10 representing "pain as bad as you can
imagine").

4. Stable analgesic regimen during the 4 weeks prior to enrollment.

5. Inadequate pain relief (minimum = 5 mean on Brief Pain Inventory-Severity Scale)
lasting more than 3 months.

6. In the judgment of the Investigator, acceptable general medical condition

7. Life expectancy >6 months

8. Male participants who are heterosexually active and not surgically sterile must agree
to use effective contraception, including abstinence, for the duration of the study
and for 3 months after the study is completed.

9. Have suitable knee joint anatomy for intra-articular injection

10. Willing and able to return for the follow-up (FU) visits

11. Able to reliably provide pain assessment

12. Able to read and understand study instructions, and willing and able to comply with
all study procedures
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Hypersensitivity, allergy, or significant reaction to any ingredient of the study
drug, including double-stranded DNA, mannose, and sucrose

2. Scheduled knee replacement within 4 months; participant agrees not to schedule a knee
replacement appointment within 4 months of study treatment

3. History of rheumatoid arthritis of the knee or gout.

4. High peri-operative risks which in the judgment of the investigator preclude a safe
knee injection procedure (e.g., poorly controlled diabetes, cardiac inadequacy such as
NYHA class > II, G4 glomerular filtration rate [eGFR < 30 mL/min by Cockcroft-Gault])

5. Current treatment with immunosuppressive (systemic corticosteroid therapy [equivalent
to >10mg/day prednisone] or other strong immunosuppressant)

6. History of immunosuppressive therapy; high-potency systemic steroids in the last 3
months.

7. Currently receiving systemic chemotherapy or radiation therapy for malignancy

8. Clinically significant hepatic disease as indicated by clinical laboratory results =3
times the upper limit of normal for any liver function test (e.g., aspartate
aminotransferase, alanine aminotransferase, lactate dehydrogenase)

9. Severe anemia (Grade 3; hemoglobin <8.0 g/dL, <4.9 mmol/L, <80 g/L; transfusion
indicated), uncontrolled coagulopathy (Grade 1, prolonged activated partial
prothrombin time (aPTT) > upper limit of normal (ULN) to 1.5xULN), or bleeding
diathesis, Grade 1 white cell counts (lymphocytes <LLN - 800/mm3; <LLN - 0.8 x 109 /L,
neutrophils <LLN - 1500/mm3; <LLN - 1.5 x 109 /L)

10. Significant neuropsychiatric conditions; dementia, major depression, or altered mental
state that in the opinion of the Investigator will interfere with study participation

11. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical
treatments)

12. Current treatment with anticoagulants, other than low-dose aspirin.

13. Known or suspected history of active alcohol or intravenous/oral drug abuse within 1
year before the screening visit

14. Women of child-bearing potential

15. Use of any investigational drug, other than XT-150, or device within 1 month before
enrollment or current participation in a trial that included intervention with a drug
or device; or currently participating in an investigational drug or device study.

16. Any condition that, in the opinion of the Principal Investigator, could compromise the
safety of the participant, the participant's ability to communicate with the study
staff, or the quality of the data

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/03/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/12/2019
Sample size
Target
Accrual to date
Final
16
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX Clinical Research Pty Ltd in collaboration with University of Adelaide - Adelaide
Recruitment postcode(s) [1] 0 0
5005 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Xalud Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
XT-150 safety and efficacy in severe osteoarthritic pain.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03769662
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mark Rickman, MD
Address 0 0
University of Adelaide
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03769662